Lips, cheeks and jawlines have dominated injectable aesthetics for years. In 2026, temple filler and temple rejuvenation are receiving more attention as practitioners look beyond isolated features and towards whole-face assessment.
Temple volume can change with age, weight loss and individual anatomy. Because the temples form part of the transition between the forehead, brow and midface, hollowing in this area may influence how balanced, rested or youthful the face appears as a whole.
A new United States dermal filler approval in March 2026 brought this frequently overlooked area into the international spotlight. For UK practitioners, however, the useful lesson is not to import a US indication. It is to recognise the growing emphasis on facial balancing, facial harmonisation, anatomy-led assessment and product-specific decision-making.
Why Are Temples Becoming a Focus in Aesthetics?
Temple volume loss may contribute to a hollowed or concave appearance between the lateral forehead, brow and cheek. It can also alter the visual transition from the upper face into the midface.
Patients do not always identify the temples as the source of their concern. They may simply say they look tired, drawn, hollow or older. That makes careful consultation and whole-face assessment particularly important.
Instead of automatically adding volume to commonly requested areas, the practitioner can consider whether a change elsewhere is affecting the patient’s overall proportions. Assessment may include:
- the relationship between the temple, brow, forehead and cheek;
- changes in facial fat compartments and skeletal support;
- skin quality, tissue thickness and visible vessels;
- asymmetry and baseline anatomy;
- previous filler or other aesthetic procedures; and
- whether treatment is appropriate at all.
Understanding the differences between dermal fillers, their rheological characteristics, intended purposes and placement requirements is essential. Products should never be assumed to be interchangeable simply because they share a broad category.
Why Is Temple Filler Trending in 2026?
On 20 March 2026, the US Food and Drug Administration approved an expanded indication for Restylane Contour for correction of temple hollowing in patients over 21. Galderma announced the decision on 23 March 2026 and noted that Restylane Contour is known as Restylane VOLYME outside the United States.
The development matters because it reflects a wider direction in aesthetic medicine: moving beyond isolated features and considering facial proportions, volume distribution and overall balance.
It must also be interpreted correctly. The approval is specific to the United States. It does not create or change a UK intended purpose, and it should not replace the current UK instructions for use supplied with an exact product.
UK practitioners should evaluate products according to the documentation applicable in the UK, their own competence, the patient’s anatomy and the proposed treatment plan. A brand-family relationship or overseas approval is not sufficient evidence that a particular UK pack is appropriate for a particular use.
Source context: Galderma’s March 2026 announcement and the FDA premarket approval supplement.
Explore Temple Fillers for Your Clinic
Review Longeva Aesthetics’ professional temple filler range, covering established brands and products for appropriately qualified practitioners.
From Facial Enhancement to Facial Balance
Many patients do not want to look dramatically different. They want outcomes that appear subtle, proportionate and natural-looking.
For an appropriately selected patient, this may involve considering less obvious areas of volume change rather than repeatedly adding volume to the most popular treatment areas. The temples sit between the upper and midface, so changes there can affect the broader impression of facial shape and continuity.
The objective is not necessarily more filler. It is better assessment and more considered product selection.
This is the distinction between treating a feature and planning for facial balance. Facial harmonisation should not mean filling every region; it means understanding how the regions relate and selecting the minimum appropriate intervention—or no intervention—according to the patient’s needs.
Practitioners reviewing different approaches to facial volume can browse Longeva’s dermal filler brands and products and read the clinical guide to dermal fillers for UK practitioners.
Temple Treatment Requires Advanced Anatomical Knowledge
The temple is an anatomically complex and potentially high-risk treatment area. Important vascular, neural and fascial structures occupy different planes, and anatomy varies between individuals.
Treatment therefore requires detailed anatomical knowledge, product-specific training, appropriate technique, careful patient selection and a clear complication-recognition and escalation pathway.
Not every patient showing temple hollowing requires temple filler. The appearance may relate to skeletal anatomy, fat distribution, muscle, skin quality, ageing, weight change or a combination of factors. Some concerns may be better addressed with another modality, while others may not warrant intervention.
Practitioners should consider:
- the exact product and formulation;
- the manufacturer’s current UK instructions for use and intended purpose;
- appropriate depth and technique for the proposed treatment;
- the practitioner’s specific training and competence;
- previous implants or procedures in the area;
- patient medical history, medicines and risk factors; and
- informed consent, emergency preparedness and follow-up.
What Makes Temple Filler Different From Cheek or Lip Filler?
“Dermal filler” describes a broad product category, not a single interchangeable material. Products differ in composition, concentration, cross-linking, firmness, cohesivity, tissue integration, intended purpose and injection requirements.
The temple also differs anatomically from the lip, cheek and jawline. A technique, volume or product used successfully in one area cannot simply be transferred to another.
This is why a trend-led request must be converted into an assessment-led plan. The patient’s desired outcome matters, but it does not determine product selection or anatomical suitability on its own.
Temple Rejuvenation After Weight Loss
Significant weight loss can make temple hollowing and broader facial volume changes more noticeable. Online, these changes are sometimes described as “Ozempic face”, “Mounjaro face” or “GLP-1 face”, although none of these expressions is a diagnosis.
Post-weight-loss assessment should consider the entire pattern of change rather than treating one hollow in isolation. Stable weight, skin laxity, midface support, tissue quality and patient expectations may all influence whether an injectable treatment is appropriate.
Read our UK practitioner guide to GLP-1 face after weight loss for a broader assessment-led discussion.
Is Whole-Face Assessment the Bigger Aesthetics Trend?
Temple rejuvenation represents something larger than the popularity of one treatment area.
An isolated-feature approach may begin with a checklist:
- lips;
- cheeks; and
- jawline.
A whole-face assessment asks different questions:
- Where has volume changed?
- How have facial proportions and transitions changed?
- What is actually creating the patient’s concern?
- Is the primary issue volume, structure, skin quality, laxity or a combination?
- Which treatment, if any, is appropriate?
This moves the conversation away from asking where filler can be placed and towards understanding why treatment is being considered. As demand continues to favour subtle, natural-looking outcomes, that distinction becomes increasingly important.
What Should UK Aesthetic Practitioners Take From the US Trend?
The US temple-filler development is commercially and clinically interesting, but it should be treated as evidence of a direction in global aesthetics—not as UK product authorisation.
The practical lessons for UK practitioners are:
- temple hollowing can influence whole-face balance even when patients do not name it directly;
- facial assessment should extend beyond the feature initially requested;
- anatomical complexity must shape training, product choice and risk management;
- overseas approvals must not be substituted for current UK product information; and
- subtle outcomes often begin with restraint and accurate diagnosis of the aesthetic concern.
The future of facial filler may therefore be less about adding more volume and more about understanding where volume is genuinely needed.
Frequently Asked Questions
What Is Temple Filler?
Temple filler is an informal term for injectable treatment intended to address volume change in the temporal region. The exact product, intended purpose, technique and suitability must be established by an appropriately qualified practitioner using current product information.
Why Do Temples Become Hollow?
Temple hollowing may reflect age-related changes in bone, muscle, fat compartments and skin, as well as genetics, baseline anatomy or significant weight loss. The cause and pattern vary between patients.
Is Temple Filler the Same as Cheek Filler?
No. The anatomy, risk profile, treatment objective and appropriate product characteristics may differ. Products and techniques should not be transferred between areas without product-specific evidence, training and assessment.
Is Temple Filler High Risk?
The temple is anatomically complex and contains important vascular and neural structures. Treatment requires advanced anatomical knowledge, appropriate training, careful technique and robust complication planning.
Does the 2026 US Approval Apply in the UK?
No. The March 2026 FDA decision concerns a US indication for Restylane Contour. UK practitioners must refer to the current UK instructions for use and intended purpose for the exact product they hold.
How Long Does Temple Filler Last?
Duration varies with the exact product, patient, anatomy, technique and other factors. Practitioners should use manufacturer information applicable to the specific product and avoid guaranteeing a fixed duration.
Explore Temple Fillers at Longeva Aesthetics
Longeva Aesthetics supplies a broad selection of professional aesthetic products for appropriately qualified UK practitioners and clinics.
Whether you are replenishing established lines or reviewing the composition, formulation and intended purpose of different options, explore the live Temple Fillers Collection.
Professional information: This article is intended for appropriately qualified and trained healthcare and aesthetic practitioners in the United Kingdom. It provides general educational information and does not constitute clinical advice or replace the current manufacturer instructions for use, product-specific training, clinical judgement, informed consent or applicable professional and legal requirements. Practitioners remain responsible for patient assessment, product selection, treatment within competence and complication preparedness.